The consistent overexpression of NUDT1 across tumor samples and its association with poor prognosis, alongside its regulatory relationship with HIF2α and impact on key cellular pathways, strongly position MTH1 (the protein product of NUDT1) as a promising biomarker candidate for RCC. This evidence concerns the gene EPAS1 and renal cell carcinoma.